Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases.
Business Model:
Revenue: $0
Employees: 1-10
Address: One Broadway
City: Cambridge
State: MA
Zip: 02142
Country: US
Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases. The company focused on the next generation of immuno-modulators by harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation specifically and profoundly. A combination of cutting-edge technologies and deep biological insights form Aviceda’s engine of transformative product creation. Aviceda uses their cell-based high-throughput screening (HTS) platform, they can rapidly screen, select, and optimize ligands based on maximum affinity and specificity for each different type of innate immune cell. . The company&s;s products are for eye diseases, fibrosis, neurology, and oncology, for eye diseases like AVD-104, AVD-302, AVD-401 for dry eye, diabetic retinopathy and retinoblastoma respectively AVD-601, AVD-701 and AVD-801 for oncology, neurology and fibrosis respectively, enabling patients to address the innate immune system and chronic non-resolving inflammation. It was founded in 2018 and is headquartered in Cambridge, MA, USA.
Contact Phone:
+16172254343
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 3/2022 | Venture Round | $49.5M | 9/2020 | Venture Round | $4.3M |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|